ETF Managers Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

ETF Managers Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-18,833	Closed	-$1.58M	–	715
2022 Q2	$1.58M	Buy	+18,833	New	+$1.5M	0.05%	185
2018 Q2	–	Sell	-801	Closed	-$62K	–	499
2018 Q1	$62K	Buy	801 +100	+14%	+$8.58K	﹤0.01%	490
2017 Q4	$64K	Buy	701 +100	+17%	+$8.7K	﹤0.01%	439
2017 Q3	$56K	Buy	601 +56	+10%	+$4.95K	﹤0.01%	315
2017 Q2	$50K	Buy	+545	New	+$49.6K	﹤0.01%	364
2016 Q1	$27K	Buy	+307	New	+$25K	0.02%	385

Other funds holding BMRN

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

ETF Managers Group's BMRN Position: Q3 2022 in Review

ETF Managers Group sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2022, closing a stake of 18,833 shares — an estimated $1.58M sold.

ETF Managers Group first reported a position in BMRN in Q1 2016 and held it in 6 quarters. The position peaked at $1.58M in Q2 2022. 551 funds tracked by Wall St. Rank hold BMRN as of Q3 2022.

ETF Managers Group reported no remaining BioMarin Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
ETF Managers Group sold 18,833 BioMarin Pharmaceuticals shares in Q3 2022, an estimated $1.58M.
ETF Managers Group first reported a position in BioMarin Pharmaceuticals in Q1 2016 and held it in 6 quarters.
ETF Managers Group's BioMarin Pharmaceuticals position peaked at $1.58M in Q2 2022.
551 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2022.

Based on ETF Managers Group's 13F filing for Q3 2022, filed 14 Nov 2022.